TD Cowen initiated coverage of OrthoPediatrics (KIDS) with a Buy rating and $23 price target The firm says OrthoPediatrics is the “clear leader” in pediatric orthopedics, with visibility to “outsized” market share in trauma, deformity and scoliosis. The company’s financial profile should support sustained low-double-digit revenue growth, improving EBITDA, and near-term free cash flow breakeven, none of which is priced into the stock’s valuation, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics (KIDS): Pediatric Ortho Leader in an Underpenetrated Market with Improving Profitability and Valuation Upside
- OrthoPediatrics: Strengthening Fundamentals, Sustained Double-Digit Growth, and Improving Cash Generation Support Buy Rating
- OrthoPediatrics Highlights Growth Strategy in 2026 Investor Presentations
- OrthoPediatrics sees FY25 revenue $236.1M, consensus $233.99M
- OrthoPediatrics sees FY26 revenue $262M-$266M, consensus $263.07M